Empagliflozin, Dapagliflozin And Canagliflozin Market Set to Reach $11.08 Billion by 2030

The Business Research Company

The Business Research Company's Empagliflozin, Dapagliflozin And Canagliflozin Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, June 4, 2026 /EINPresswire.com/ -- "The market for empagliflozin, dapagliflozin, and canagliflozin has demonstrated consistent growth recently, driven by rising cases of type 2 diabetes and increasing adoption of oral diabetes medications. Let’s explore the current market size, key growth factors, major players, and regional outlook to understand what lies ahead for this segment.

Steady Expansion in the Empagliflozin, Dapagliflozin, and Canagliflozin Market Size
The market valued at $9.84 billion in 2025 is projected to reach $10.07 billion by 2026, growing at a compound annual growth rate (CAGR) of 2.4%. This upward trend in the recent past has been influenced by several factors, such as the increasing prevalence of type 2 diabetes, wider acceptance of oral diabetes drugs, updates to clinical guidelines, heightened awareness of cardiovascular risks, and the overall rise of lifestyle-related diseases.

Download a free sample of the empagliflozin, dapagliflozin and canagliflozin market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=May_PR

Future Growth Expectations for the Empagliflozin, Dapagliflozin, and Canagliflozin Market
Looking ahead, the market is anticipated to continue its steady rise, reaching $11.08 billion by 2030 with the same CAGR of 2.4%. Key drivers during this forecast period include the broader use of these drugs for heart failure treatment, growing clinical evidence supporting renal protection, increased use of combination therapies for diabetes, an aging global population, and a stronger focus on managing chronic diseases. Emerging trends point to expanding applications of SGLT-2 inhibitors in type 2 diabetes, more cardiovascular benefit indications, a rising preference for oral antidiabetic medications, growth in combination therapies, and an emphasis on long-term blood sugar control.

Understanding Empagliflozin, Dapagliflozin, and Canagliflozin as SGLT-2 Inhibitors
Empagliflozin, dapagliflozin, and canagliflozin belong to the sodium-glucose co-transporter-2 (SGLT-2) inhibitor class. These oral medications are primarily prescribed to manage type 2 diabetes mellitus and are often used alongside lifestyle modifications like diet and exercise, as well as other diabetes treatments, to effectively control blood sugar levels.

View the full empagliflozin, dapagliflozin and canagliflozin market report:
https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=May_PR

What Factors Are Propelling the Empagliflozin, Dapagliflozin, and Canagliflozin Market?
The growing prevalence of type 2 diabetes remains a primary driver for the market. Increasing awareness about the benefits of oral diabetes medications, updates in clinical guidelines favoring these drugs, and a heightened focus on cardiovascular health collectively contribute to the market’s steady growth.

Additionally, the expanding evidence supporting their role in treating heart failure and protecting kidney function is pushing the adoption of these drugs beyond traditional diabetes management. This, combined with an aging population and a growing focus on chronic disease management, is sustaining the demand for these treatments.

Regional Overview of the Empagliflozin, Dapagliflozin, and Canagliflozin Market
In 2025, North America emerged as the largest market region for empagliflozin, dapagliflozin, and canagliflozin. The market report covers other important regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive view of the global landscape and regional dynamics influencing market growth.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Browse Through More Reports Similar to the Global Empagliflozin, Dapagliflozin And Canagliflozin Market 2026, By The Business Research Company

Transplant Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/transplant-diagnostics-global-market-report

Blood Transfusion Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Cancer Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.